Compare Grab Holdings Ltd. (GRAB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Regeneron Pharmaceuticals Inc — how do they compare? Grab Holdings Ltd. trades at $3.76 (market cap $15.62B), while Regeneron Pharmaceuticals Inc trades at $676.01 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.5× Grab Holdings Ltd.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| GRAB | REGN | |
|---|---|---|
Market Cap | $15.62B | $69.66B |
Sector | Technology | Health |
52-Week High | $6.45 | $812.27 |
52-Week Low | $3.27 | $542.52 |
Enterprise Value | $11.32B | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.80, down 3.55% today but showing strong fundamental improvement with revenue growth from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Technical indicators show a bullish overall signal with neutral oscillators. Recent news highlights CEO share sales and Uber CEO's board departure, creating mixed sentiment despite analyst optimism.
The outlook remains positive with 91.67% analyst buy ratings and a $5.45 consensus target offering 43% upside. Key risks include competitive pressures in Southeast Asia's ride-hailing market and volatile cash flow patterns, but sustained revenue growth and margin expansion support long-term potential.
Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.
Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
